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The targeting of self-renewal pathways commonly activated in leukemia serves as a potential strategy for multiple subtypes of this disease regardless of genetic, clonal or cellular heterogeneity. Elevation of b-catenin above physiological conditions enhances the self-renewal of normal hematopoietic stem cells (HSCs), and this attribute appears to be commonly utilized by leukemia cells. 1 Dependency on elevated b-catenin activity in leukemia stem cells (LSCs) demonstrated in several different types of leukemia strongly suggests an essential and universal role for b-catenin in LSC function in leukemia. [2] [3] [4] [5] [6] As normal adult HSCs do not require its basal activity, 7 b-catenin has emerged as a potential LSCspecific therapeutic target.
Mutations in the Ras pathway are some of the most common in all human malignancies and occur across the spectrum of human blood neoplasms. 8 These mutations usually in KRAS, NRAS or NF1
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Letters to the Editor lead to stabilization of the GTP-bound active state of small Ras GTPases leading to over-activation of downstream Ras effector pathways. 8 Endogenous levels of gain-of-function Ras proteins in mice lead to myeloproliferative neoplasms (MPNs) and/or T-cell acute lymphoblastic leukemia (T-ALL). [9] [10] [11] Although this pathway has been intensely studied, direct pharmacological inhibition of mutant Ras proteins has proven to be extremely challenging.
To determine if b-catenin is required for activated-Ras pathwayevoked leukemia, we first utilized mice that express from the endogenous promoter a conditionally active gain-of-function allele of KRas (loxp-stop cassette-loxp [LSL]-KRas G12D ), that develop a juvenile myelomonocytic leukemia /chronic myelomonocytic leukemia-like MPN upon Cre-mediated excision of the stop cassette.
9,10 LSL-KRas G12D mice were crossed with mice carrying conditional loss-of-function alleles of b-catenin and to interferoninducible transgenic-Mx1Cre mice, allowing for recombination upon administration of pIpC. However, we found as previously reported, 7 that pIpC administered to Mx1Cre;b-catenin loxp/loxp mice results in early non-hematopoietic lethality (data not shown). Consistent with previous results, we found highefficiency spontaneous excision of the stop casette in the absence of Cre induction and found that b-catenin could also be excised concurrently in the Mx1Cre þ LSL-KRas G12D setting ( Figure 1a) . 10, 11 We thus utilized mice of the following genotypes, Mx1Cre
KRas G12D ) and assessed them without pIpC administration. We confirmed Cre-mediated (in the absence of pIpC administration) excision within the b-catenin locus by quantitative real-time PCR (qRT-PCR), as early as 4 weeks of age, in the peripheral blood of bCat þ / À KRas G12D and bCat À / À KRas G12D mice (data not shown) and in the bone marrow (BM) of 13-17 weeks old mice (Figure 1a) . We found no statistical differences in the survival of all mice expressing oncogenic KRas G12D , regardless of b-catenin status (Figure 1b) Figure S1 and Supplementary Table S1 ). Transplanted KRas G12D -expressing BM cells give rise to an aggressive T-ALL. 11 To determine the requirement for b-catenin in KRas G12D -induced T-ALL, we transplanted donor BM cells with helper cells into lethally irradiated congenic recipient mice, and found that all KRas G12D -expressing cells, regardless of b-catenin status, exhibited increased chimerism (480%) when compared with mice transplanted with control (bCat loxp/loxp ) BM cells (B60%) (Figure 1c ). All mice transplanted with KRas G12D -expressing BM cells, even those with loss of b-catenin, were moribund within 3.5 months of transplant, whereas none of the recipients transplanted with control cells died during this observation period (Figure 1d and Supplementary Figure S2a and S2b). Consistent with previous findings, 11 we found that all recipient mice transplanted with KRas G12D -expressing cells developed both a mild MPN (Supplementary Table S1 and data not shown), and a more aggressive T-ALL disease, characterized by thymus enlargement filled with abnormal CD8 þ single-positive and CD4 þ CD8 þ double-positive cells (Supplementary Table S1 and Supplementary Figure S2c) .
To further assess the role of b-catenin in KRas
-induced T-ALL, we performed a secondary limiting-dilution transplant using thymocytes from primary recipients for injection into sublethally irradiated recipients. Despite a slight difference in the frequency of leukemia-initiating cells (LICs) (Supplementary Table S2a), the loss of b-catenin did not alter neither the survival nor the disease phenotype of mice transplanted with KRas We and others demonstrated that b-catenin is required for mixed-lineage leukemia (MLL)-rearranged-driven acute myeloid leukemia (AML). 4, 5 As Ras pathway mutations are common in AML and can co-occur with MLL rearrangements, 4, 5 we sought to determine if b-catenin would still be required for leukemogenesis in a KRas G12D -expressing MLL-rearranged setting. We transduced the hematopoietic stem and progenitor cell (HSPC)-enriched Lin À Sca-1 þ c-Kit þ (LSK) cell fraction with MSCV-MLL-AF9-ires-GFP retrovirus from the following mice:
À bCat loxp/loxp and MxCre þ bCat loxp/loxp ; and transplanted these cells into sublethally irradiated C57BL/6 recipients. We found that mice transplanted with KRas G12D MLL-AF9 cells, regardless of b-catenin status, developed a lethal AML, characterized by leukocytosis and splenomegaly with myeloid infiltration (Figure 2a Table S2b ). In an attempt to decipher the underlying molecular mechanisms for this compensation, we performed gene expression analysis using RNA from LSC-enriched Lin À Kit hi GFP hi BM cells of secondary AML transplant recipients and found that gene expression levels which were altered with the loss of b-catenin in MLL-AF9 were in part rescued with the co-expression of KRas G12D in AML (Figure 2d ). In particular, CD99 and DPPIV piqued our interest as they displayed changes in surface expression due to loss of b-catenin in MLL-AF9 AML and are brought to normal levels upon KRas G12D expression (Figure 2d and Supplementary Figure S5b) .
We found that b-catenin is dispensable for leukemogenesis evoked by expression of KRas
. Furthermore, KRas G12D expression appears to rescue the effects of b-catenin loss in an MLL-AF9 AML model. We sought to determine if self-renewal pathways activated by b-catenin are generally required in leukemia, and found that in contrast to BCR-ABL-driven CML, 2, 6 MLL-rearrangement-driven AML 4, 5 and Pten-loss-driven T-ALL, 3 KRas G12D can function independently or in parallel to b-catenin-dependent pathways to generate leukemia. These data suggest alternative mechanisms of leukemogenesis and leukemia maintenance independent of b-catenin, and are in line with data demonstrating the lack of major effects due to b-catenin knockdown in leukemia generation by some primary human AML samples. 12 In keeping with our previous findings, we found differential dependence on betacatenin in MLL-AF9 leukemia. 4, 13 It is important to note that AMLs derived from granulocyte monocyte progenitor cells show a much more absolute dependence on b-catenin than do LSK-derived AML cells, further supporting the findings that the cell of origin influences pathway dependencies in the fully developed leukemia (A.K. unpublished data). 4, 13 Our analysis has also uncovered potential mechanisms of bypassing the need for b-catenin. Of note, CD99 levels diminish upon loss of b-catenin in our AML model, but are rescued upon induction of KRas G12D (Figure 2d and Supplementary Figure S5b) . Significantly, CD99 expression is high in human LSC.
14 DPPIV/CD26 levels, on the other hand, increase upon b-catenin loss in our AML model, and its levels remain decreased upon KRas G12D induction in the absence of b-catenin (Figure 2d and Supplementary Figure S5b) . Interestingly, DPPIV/CD26 was previously demonstrated to impede HSC function, and our data suggest it may act similarly in leukemia cells. 15 In this study, we demonstrated that b-catenin is not universally required for leukemia development. We have specifically shown that activated KRas can bypass the need for this molecule in leukemogenesis and propose a potential mechanism of resistance to b-catenin inhibition in cancer. βCat -/-KRas G12D MLL-AF9 Chronic myeloid leukaemia (CML) is characterised by the t(9;22)(q34;q11) translocation, resulting in the Bcr-Abl oncoprotein which can be targeted by tyrosine kinase inhibitors (TKIs). However, the clinical response to TKIs between patients is highly variable. Protein tyrosine phosphatase, non-receptor type 2 (PTPN2) is a member of the protein tyrosine phosphatase family. PTPN2 gene expression is associated with 'stemness' across the haematopoietic stem cell, embryonic stem cell and neural stem cell subpopulations. 1 PTPN2 has also been shown to regulate the functions of Bcr-Abl and c-Abl, 2 as well as the phosphorylation status of STAT1 3 and STAT5. 4 Previous studies have demonstrated that reduced PTPN2 expression is associated with resistance to imatinib, but sensitivity to interferon-alpha in a BCR-ABL1 þ cell line, KT-1. 5 However, no studies have been performed investigating PTPN2 expression in primary CML patient samples. Therefore, we sought to investigate the impact of PTPN2 expression on clinical response in a cohort of de-novo chronic-phase CML (CP-CML) patients.
A total of 93 mRNA samples, prepared from patient mononuclear cells (MNCs) isolated from blood collected at diagnosis (prior to imatinib treatment), were analysed. PTPN2 gene expression was measured using the Affymetrix Human Gene 1.0 ST microarray, as previously described. 6 Briefly, analysis of the microarray data included normalisation by Robust multi-array average (RMA) using the aroma.affymetrix package, with custom annotation (Brainarray Entrez Gene 16.0), in the R statistical program (v2.15.1). Event-free survival (EFS) and mutation-free survival (MFS) were calculated by the Kaplan-Meier method using SPSS statistical software (IBM Corporation, Armonk, NY, USA). Molecular responses were calculated by cumulative incidence using a Fine and Gray model implemented in the R package 'cmprsk', and by multivariate Cox regression analysis. In the competing risk regression models, an event was defined by achievement of the desired response, while cessation of TKI for any reason (including death) was the competing risk. All further statistical analyses were performed using GraphPad Prism v6.0.
The total patient cohort was separated into two groups based on PTPN2 expression. High PTPN2 expression (n ¼ 23) was defined as the top 25% (PTPN2 expression X7.78), whereas patients with PTPN2 expression o7.78 were defined as low PTPN2 expression (n ¼ 70). Next, we investigated the association between PTPN2 expression and clinical outcome. Data from 71 patients treated in Adelaide (with response data available) under the imatinib treatment protocol were available for analysis. However, only 70
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